Summary
The aim of this study was to evaluate the usefulness of cyclosporin in Behçet's disease. Sixteen subjects (10 males and 6 females; mean age 25.2 years) affected by the complete type of Behçet's syndrome received 5 mg/kg/day of cyclosporin for 24 months. A marked improvement of the symptoms was observed after three months of therapy. Within 6 to 12 months of treatment 14 of the 16 patients obtained a complete clinical remission. Biochemical and immunological parameters were controlled periodically to evaluate the clinical response and the possible side-effects. Two patients dropped out of the study because of anaemia and renal dysfunction, which returned to normal when cyclosporin was withdrawn. Our results confirm the efficacy of cyclosporin in the treatment of Behçet's disease.
Similar content being viewed by others
References
Yazici, H., Akokan, G., Yalcin, B., Muftuogla, A. The high prevalence of HLA-B5 in Behçet's disease. Clin Exp Immunol 1977, 30, 259–261.
Ohno, S., Aoiki, K., Suguira, S., Nakayama, E., Ikatura, K., Aizawa, M. HLA-B5 and Behçet's disease. Lancet 1973, ii, 1383–1384.
Lehner, T., Welsh, K.L., Batchelor, J.R. The relationship of HLA-B and DR phenotypes to Behçet's syndrome, recurrent oral ulceration and the class of immune complexes. Immunology 1982, 47, 581–587.
Lehner, T., Almeida, J.D., Levinsky, R.J. Damage membrane fragments and immune complex in the blood of patients with Behçet's syndrome. Clin Exp Immunol 1978, 34, 206–212.
Levinsky, R.J., Lehner, T. Circulating soluble immune complexes in recurrent oral ulceration and Behçet's syndrome. Clin Exp Immunol 1978, 32, 193–198.
Williams, B.D., Lehner, T. Immune complexes in Behçet's syndrome and recurrent oral ulceration. B Med J 1977, 1, 1387–1389.
Lim, S.D., Haw, C.R., Kim, N.I., Fusaro, R.M. Abnormalities of T-cell subsets in Behçet's syndrome. Arch Dermatol 1983, 119, 307–311.
O'Duffy, J.D., Robertson, D.M., Goldstein, N.P. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. Am J Med 1984, 76, 75–84.
Tabbara, K.F. Chlorambucil in Behçet's disease, a reappraisal Ophtalmology 1983, 90, 906–908. Br J Ophthalmol 1976, 60, 55–57.
Triculis, D. Treatment of Behçet's disease with chlorambucil. Br J Ophtamol 1976, 60, 55–57.
Oniki, S., Kurakazu, K., Kawata, K. Immunosuppressive treatment of Behçet's disease with cyclophosphamide. Jpn J Ophtalmol 1976, 20, 32–40.
Rosselet, E., Saudan, Y., Znkusen, G. Les effects de la Azathioprine dans le maladie de Behçet. Premiers resultats therapeutiques. Ophthalmologica 1968, 156, 218–222.
Saito, K., Ohguchi, M., Sugiura, S. Colchicine treatment in Behçet's disease. Ophthalmology 1977, 19, 115–120.
BenEzra, D., Cohen, E., Chajek, T., Friedman, G., Pizanti, S., de Courten, C., Harris, W. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988, 3, 136–143.
Nussenblatt, R.B., Rodrigues, M.M., Wacker, W.B., Cevario, S.J., Salinas-Carmona, M.C. Cyclosporin A: inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest 1981, 67, 1228–1231.
Nussenblatt, R.B., Palestine, A.G., Chi-Chao, C., Manabu, M., Yancey, K. Effectiveness of cyclosporin therapy for Behçet's disease. Arthritis Rheum 1985, 28, 671–679.
Choen, D.J., Loertscher, R., Rubin, M.F. Cyclosporin: a new immuno-suppressive agent for organ transplantation. Ann Int Med 1984, 101, 667–682.
Borel, J.F., Lafferty, K.J. Cyclosporin: speculation about its mechanism of action. Transplant Proc 1983, 15, 1881–1885.
Nanba, K., Masuda, K. Clinical features of severe case with Behçet's disease. Jpn J Clin Ophthalmol 1982, 36, 1241–1245.
Nussenblatt, R.B. The use of cyclosporine in ocular inflammatory disorders. Transplant Proc 1988, 81, 545–546.
Ohno, S. Immunological aspects of Behçet's, Vogt-Koyonagi and Harada's diseases. Trans Ophtalmol Soc UK 1981, 101, 335–341.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pacor, M.L., Biasi, D., Lunardi, C. et al. Cyclosporin in Behçet's disease: Results in 16 patients after 24 months of therapy. Clin Rheumatol 13, 224–227 (1994). https://doi.org/10.1007/BF02249016
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02249016